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Abstract
Ribosome-inactivating proteins (RIPs) are endowed with several medicinal properties, including antiviral activity. We
demonstrate here that the recently identified type I RIP from Momordica balsamina also possesses antiviral activity, as
determined by viral growth curve assays and single-round infection experiments. Importantly, this activity is at play even as
doses where the RIP has no cytotoxic effect. In addition, balsamin inhibits HIV-1 replication not only in T cell lines but also in
human primary CD4+ T cells. This antiviral compound exerts its activity at a viral replicative step occurring later than reverse-
transcription, most likely on viral protein translation, prior to viral budding and release. Finally, we demonstrate that
balsamin antiviral activity is broad since it also impedes influenza virus replication. Altogether our results demonstrate that
type I RIP can exert a potent anti-HIV-1 activity which paves the way for new therapeutic avenues for the treatment of viral
infections.
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Introduction
Ribosome-inactivating proteins (RIPs) are RNA N-glycosidases
which cleave N-glycosidic bond of adenine A2660 in Escherichia coli
23 S rRNA or A4324 in eukaryotic 28 S rRNA located in a highly
conserved a-sarcin/ricin (SR) loop on the rRNA. This results in
depurination of SR loop and inability of the ribosome to bind
elongation factor 2 and thus inhibit protein synthesis [1]. RIPs are
classified into three types: Type I RIP, which are single chain
highly basic proteins of approximately 30 kDa and possess
enzymatic activity; Type II RIP, which are heterodimeric proteins
composed of an enzymatically active A chain of approximately
30 kDa and a lectin-like B-chain of approximately 35 kDa [2];
and type III RIPs, which consist of a single enzymatically active
polypeptide that is synthesized as a zymogen [3]. Type II RIPs
such as ricin are usually more toxic than type I RIPs [4].
Ribosome inactivating proteins (RIPs) have multiple biological
properties comprising anti-tumor, antiviral, abortifacient, and
immunosuppressive activities either alone or conjugated with
antibody as immunotoxins [5]. RIPs-based immunotoxins have
been prepared for antitumor [6] and antiviral therapy [7].
RIPs are found abundantly in the seeds of several plant families,
amongst which Caryophyllaceae, Cucurbitaceae, Euphorbiaceae
and Phytolaccaceae. Several RIPs have been purified and
investigated for their potential medicinal usage, including
Momordica charantia, Gelonium multiflorum, Phytolacca americana,
Trichosanthes kirilowii, Luffa cylindrica, Bryonia dioica, Dianthus
caryophyllus, Ricinus communis and Abrus precatorius [8]. Importantly,
many type I and type II RIPs, amongst which a-and b-MMC,
MAP30, GAP31, TAP29, DAP30, DAP32, TCS, PAP, bryodin
and ricin, have been reported to inhibit HIV-1 replication in vitro
and in vivo [9]. Nevertheless, the anti-HIV mechanism of ribosome
inactivating protein is still not clear.
Extracts from Momordica charantia, which belongs to the
Cucurbitaceae family, have been used as therapeutic agent for
centuries. Accordingly, fruits and seeds extracts of this plant have
been shown to possess in vivo anti-tumor activity, immune
enhancement ability and effect on HIV-1 [10]. In recent years,
several type I RIPs have been isolated from this edible plant,
namely a-momorcharin, b-momorcharin, MAP30, c-momorch-
arin, d-momorcharin, e-momorcharin and charantin [11]. While
all of these RIPs are endowed with N-glycosidase activity, only
MAP30, a-and b-momorcharins were shown to possess anti-HIV
activity [4]. While alpha momorcharin inhibits HIV replication in
both acutely infected lymphoblastoid cells and chronically infected
macrophages [12], MAP30 has anti-tumor activity and inhibits
HIV-1 infection in both T cells and macrophages [13].
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Momordica balsamina (commonly known as Balsam apple, bitter
melon), a high-climbing vine from family Cucurbitaceae, is native
to the tropical regions of Africa, Arabia, Asia and Caribbean. This
plant is a monoecious vine and found in North India [14]. While
M. balsamina solvent extract has shown in vitro and in vivo anti-
malarial activity [15], its fruit and leaves extract has anti-
hypoglycemic effect on rats [16]. Balsamin is a type I ribosome
inactivating protein of 28 kDa that has recently been isolated from
the seeds of Momordica balsamina. It inhibits protein synthesis in cell
free lysate and possesses N-glycosidase activity [17]. In the present
study, the anti-HIV-1 activity of purified balsamin was investigat-
ed. We report the inhibition of HIV-1 replication by a series of
assays in both the Jurkat T cell line and primary T cells. In
addition, we demonstrate that this antiviral factor acts by
inhibiting a late viral replicative step, most likely the viral protein
translation. Finally, we establish that balsamin antiviral activity is
broad since it also blocks influenza virus replication. These
observations may open new therapeutic avenues for the treatment
of viral infections.
Methods
Cells and Viruses
The Jurkat human T cell line was maintained in RPMI-1640
medium (Life Technologies) supplemented with 10% heat
inactivated fetal calf serum (FCS), 100 U/ml penicillin, 100 mg/
ml streptomycin and 2 mM L-glutamine. The epithelial cell lines
MDCK [18] and A549 [19] from dog and human origin
respectively, were cultured in Dulbecco’s modified Eagle’s
medium (Invitrogen) with 10% heat inactivated FCS, penicillin
and streptomycin and glutamine. Blood samples and cell protocols
were approved by the ethical committee (‘‘Commission d’e´thique
de la recherche sur l’eˆtre humain’’ of the University of Geneva
(Switzerland). Written informed consent was provided by study
participants and validated by the institutional review board.
Primary CD4+ T cells were isolated from buffy coats of healthy
seronegative blood donors. CD4+ T cells were purified from
PBMCs after Ficoll gradient separation with CD4+ T cell isolation
kit II (Miltenyi Biotec), in accordance with the manufacturer’s
instructions and maintained in RPMI 1640. Later on CD4+ T cells
were activated by PHA-L (1 mg/ml) and IL-2 (20 ng/ml) prior to
infection.
HIV-1 stock (R9 strain) was initially produced by transient
transfection of 293 T cells. For single-round infections, we used an
HIV-1 deleted for the env gene and pseudotyped with the surface
G protein of vesicular stomatitis virus (VSV). Influenza A/PR8/34
(H1N1) strain was produced by infection of MDCK cells at a moi
of 0.001, followed by culture for 72 hours in serum-free Opti-
MEM supplemented with 1 mg/ml TPCK-treated trypsin (Sigma).
Source and Purification of Balsamin
Balsamin was purified from the seeds of Momordica balsamina as
described previously [17].
Figure 1. Balsamin potently inhibits HIV-1 replication in T cell lines. A. Jurkat cells were infected with HIV-1 at a moi of 0.01, in the absence
or presence of 3.57 mM balsamin, and cell-free supernatant was collected at indicated days for monitoring HIV-1 production by RT assay or p24 capsid
ELISA. B. The values obtained in the absence of balsamin were arbitrarily set as 100%. C. On the 11th day, protein extracts were collected to analyze by
Western blot the effect of balsamin on accumulation of HIV-1 p24, p41 and p55 proteins. Actin serves as a loading control. Error bars represent 6SD
of two independent experiments performed in duplicate.
doi:10.1371/journal.pone.0073780.g001
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Protein Analysis
Cells were lysed with RIPA buffer. Resulting extract were then
pre-cleared (1090006g spin for 10 minutes), and their protein
content was quantified with the BCA kit (Thermo). Subsequent
Western blotting analyses were performed according to standard
procedures. Antibodies serving for the detection of actin (Milli-
pore) and M1 (clone GA2B, Abcam) were of mouse origin. Gag
p55 and p24 were detected with the mouse monoclonal antibody
made by Bruce Chesebro and Kathy Wehrly (obtained through
the AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH) [20].
HIV-1 Viral Particles Quantification
The production of HIV-1 viral particles was quantified by 2
methods, both on cell-free supernatant after filtration through
0.45 mm pore-size nitrocellulose membrane (Spin-X; Corning).
Firstly, the RT assay measures the reverse transcriptase (RT)
enzymatic activity in the cells supernatant and was performed
according to standard protocol [21]. Secondly, the p24-specific
ELISA assay, performed by HIV-1 p24CA Antigen Capture Assay
kit from AIDS & Cancer Virus Program, which measures the
amount of viral capsid protein in the supernatant.
T Cells Infections with Wild Type HIV-1
In the presence of indicated dose of balsamin, Jurkat T cells
(76105 cells/ml) were infected with HIV-1 at a multiplicity of
Figure 2. Determination of IC50 and cytotoxicity of balsamin. A. Dose-response curve of balsamin-mediated HIV-1 inhibition. Jurkat T cells
were infected with HIV-1 at a moi of 0.1, in the absence or presence of indicated amounts of balsamin. Eight hours post-infection, cells were washed
with PBS, and incubated further with relevant amounts of balsamin. Three days post-infection, cell free supernatant was harvested for assessing viral
replication by RT assay. This allowed us to determine that the balsamin dose at which 50% of HIV-1 replication is 10.2 nM. The section of this figure is
representative of four independent experiments. B. Monitoring in vitro cytotoxicity of balsamin. Different concentrations of balsamin (0.22, 1.12 and
3.57 mM) were applied on Jurkat T cells, and cellular viability was assessed by determining the percentage of viable cells using Trypan blue exclusion.
Data represent 6SD of two independent experiments performed in duplicate. C. Determination of TC50 of balsamin in Jurkat cells. Jurkat cells were
incubated for 48 hours with balsamin at 0.2 mM, 2 mM and 20 mM. At 48 hours cells were harvested for determination of cell viability by trypan blue
assay and cell counting. One representative experiment out of two is shown. D. Jurkat cells were treated as above in parallel with AZT and stained for
Annexin-V and 7-AAD. Viable cells (Annexin-V2/7-AAD2) were measured by FACS and plotted on a bar graph +/2 SD (n = 2 in duplicate). E. Jurkat T
cells were pre-treated with balsamin at sub-optimal concentrations (0.1 nM, 1 nM, 10 nM) for 3 hours. AZT (50 mM) was included as a positive control
of inhibition. Cells were then infected with HIV-1 at a multiplicity of infection of 1.0 for the indicated days. Viral HIV-1 p24 concentration was
measured by ELISA in harvested cell-free supernatants. A representative experiment out of two is shown with data expressed as percentage of HIV-1
p24 concentration measured in corresponding time points from supernatants of cells infected in the absence of balsamin.
doi:10.1371/journal.pone.0073780.g002
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infection (moi) of 0.01. Eight hours post-infection, the cells were
washed with PBS and incubated with or without balsamin in
culture medium. At indicated days, an aliquot of cell-free
supernatant for each sample was harvested for determination of
p24 and RT assay.
Primary CD4+ T cells (76105 cells/ml) were infected with HIV-
1 at 0.1 multiplicity of infection (moi). AZT (Azidothymidine) was
included as positive control of inhibition and three different
balsamin concentration (0.22, 1.12 and 3.57 mM) used. The wells
without protein were used as a negative control. After 8 h of
infection, cells were washed with PBS and resuspended in fresh
RPMI medium and cultured in the presence and absence of
balsamin. At indicated days post-infection cell-free supernatant
was collected to determine RT assay.
HIV-1 Single Round Infections
Primary CD4+ T cells (86105 cells/ml) were pretreated with
indicated concentrations of balsamin and with AZT as a control.
The cells without balsamin were included as a negative control.
Cells were then infected with indicated doses of HIV-1 Denv
pseudotyped with VSV G protein. Eight hours post -infection cells
were washed with PBS and cultured with different concentration
of balsamin. Forty-eight hours of post-infection, supernatant was
collected to determine reverse transcriptase activity assay. In
parallel, cell lysates were prepared for Western blot analysis.
Cellular Viability and Balsamin TC50 Determination
For cell viability, Jurkat cells or primary CD4+ T cells were
seeded at a density of 76105 in a 12 well plates. Cells were then
treated with different concentration of balsamin in duplicate and
incubated at 37uC. The wells without balsamin were used as
Figure 3. Balsamin potently inhibits HIV-1 replication in primary CD4+ T cells. A. Primary CD4+ T cells were infected with HIV-1 at a moi of
0.1, in the absence or presence of indicated amounts of balsamin. Eight hours post-infection, cells were washed with PBS, and incubated further with
relevant amounts of balsamin. Three days post-infection, cell free supernatant was harvested for assessing viral replication by RT assay. The values
obtained in the absence of balsamin were arbitrarily set as 100%. B. In parallel, cell lysates were collected and were immunoblotted for HIV-1 p24 (B,
upper panel). Actin served as a loading control, and AZT was used as a positive control for the HIV-1 inhibition. The intracellular level of p55 was
quantified and plotted (B, lower panel). The sections of this figure are representative of three donors. C. In parallel of this assay, putative cytotoxic
effect of these different concentration of balsamin on primary CD4+ T cells were monitored by determining the percentage of viable cells using
Trypan blue exclusion. Data are representative of three donors and experiments performed in duplicate (6SD). D. Primary CD4+ T cells were
incubated for 48 hours with balsamin at 0.2 mM, 2 mM and 20 mM. At 48 hours cells were harvested for determination of cell viability by trypan blue
assay and cell counting. One representative experiment out of two is shown. E. Primary CD4+ T cells were treated as above in parallel with AZT and
stained for Annexin-V and 7-AAD. Viable cells (Annexin-V2/7-AAD2) were measured by FACS and plotted on a bar graph +/2 SD (n = 2 in duplicate).
doi:10.1371/journal.pone.0073780.g003
Balsamin Inhibits HIV-1 Replication
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control. Cell suspension was collected on indicated days to assess
cell viability by counting cells in presence of Trypan blue solution.
To determine TC50 of balsamin, Jurkat or primary CD4+ T Cells
at 16105 in duplicate were incubated in 96 well plates with
Balsamin at 0.2 mM, 2 mM and 20 mM. Treatments with AZT
were also done as a drug toxicity control (not shown). Cells were
harvested two days later for determination of cell viability by
trypan blue exclusion and cell counting. In parallel, the same
methodology was done but cells were harvested, stained with PE
Annexin V Apoptosis Detection Kit I (BD Pharmingen) and viable
(Annexin V2/7-AAD2), early apoptotic (Annexin V+/7-AAD2)
and late apoptotic/necrotic (Annexin V+/7-AAD+) were deter-
mined.
Balsamin IC50 Measurement
Jurkat cells were seeded (76105 cells/ml) in 12 well plates. In
the presence of different concentration of balsamin, cells were
infected with HIV-1 at a multiplicity of infection (moi) of 0.1.
Eight hours post-infection cells were washed with PBS to remove
free virus and then again resuspended in RPMI fresh medium. On
3rd day post-infection, cell-free supernatant was collected to
perform a RT assay. The inhibition of HIV-1 replication by 50%
(IC50) was determined by plotting the results of the dose-response
in Excel, and fitting a logarithmic trendline to the curve. Using to
the equation of this trendline allowed us to determine the balsamin
dose at which 50% of HIV-1 production was inhibited.
Determination of Drug-Resistant Escape Mutant
To examine whether drug-resistant escape mutants could be
generated in the presence of sub-optimal doses of balsamin, Jurkat
T cells (16105 cells/well) were left untreated or incubated with
increasing concentrations of Balsamin (0.1 nM, 1 nM, 10 nM) for
3 hours. Cells were in parallel treated with AZT (50 mM). Cells
were then infected with HIV-1 at a multiplicity of infection of 1.0.
The day after viral challenge, cells were washed with PBS and re-
supplied with drugs. Cell free supernatants were preserved for p24
determination by ELISA.
PCR
Jurkat cell line (76105 cells/ml) was pretreated with 3.57 mM of
balsamin. The cells without balsamin were included as control.
HIV-1 was DNase-treated for 30 minutes at 37uC to avoid carry-
Figure 4. Balsamin does not inhibit early HIV-1 replication steps. A. Jurkat T cells were infected with DNase-treated HIV-1 with at a moi of 1
or 0.2. Eight hours post-infection, cells were washed with PBS and cultured in the presence or absence of 3.57 mM balsamin. Forty-eight hours later,
cell-associated DNA was isolated and subjected to PCR with HIV-specific primers. Heat-inactivated virus served as a negative control. The section of
this figure is representative of two independent experiments. B. In parallel, the effect of balsamin on HIV-1 replication was monitored by collecting
the supernatant of infected cells and measuring viral release by RT assay. The values obtained in the absence of balsamin at moi 1 were set as 100%.
Data are 6SD and representative of two independent experiments.
doi:10.1371/journal.pone.0073780.g004
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over of the plasmids used for viral particles production. Jurkat cell
line was then infected with this virus a multiplicity of infection
(moi) of 0.2 and 1. Heat inactivated virus was used as a negative
control. Eight hours post-infection, cells were washed with PBS
and cultured with 3.57 mM of balsamin. Forty-eight hours of post-
infection, total cell-associated DNA was isolated with DNeasy kit
(Qiagen) and amplified by PCR using primers targeting so-called
late reverse transcripts (forward: TGTGTGCCCGTCTGTTGTGT;
reverse: GAGTCCTGCGTCGAGAGAGC) [22]. The amplifica-
tion of actin with actin-specific primers (forward: TCACCCA-
CACTGTGCCCATCTACGA; reverse: CAGCGGAACCGCT-
CATTGCCAATGG) served as an input control. In parallel, the
supernatant was harvested to determine reverse transcriptase
activity assay.
Influenza virus Infection and Titration
A549 cells were split in 6 well plates and infected with influenza
virus (PR8). The virus infected cells were incubated in the presence
of different concentration of balsamin. The wells without protein
served as a negative control. After 16 h of incubation, cells were
twice washed with PBS and suspended in OPTI-MEM medium.
Twenty four hours after the PBS wash, supernatant was collected
and cells were detached using PBS-EDTA for protein quantifica-
tion. Virus replication was assessed by monitoring either
accumulation of influenza M1 protein in infected cells, or by
titrating the viral infectious output present in supernatant. The
titration of viral supernatants was performed by infecting MDCK
cells plated in 48 well plates with serial dilutions of the viral
supernatant. 20 hours later, cells were washed once with PBS,
fixed directly in the plate with 100% methanol at 220uC for 10
minutes, washed once with PBS, and incubated for 30 minutes at
room temperature in PBS 1% BSA. Infected cells were then
revealed by immunofluorescent staining with a FITC-coupled
anti-NP (#8257F from Millipore, at a 1/500th dilution in PBS) for
45 minutes at room temperature, followed by three PBS washes.
Titer was computed by scoring the numbers of green cells under a
fluorescence microscope.
Results
Balsamin Potently Inhibits HIV-1 Replication in T Cell
Lines
We first assessed the ability of balsamin to inhibit HIV
replication in a viral growth curve assay in Jurkat T cells.
Monitoring the release of viral proteins p24 and RT in the
supernatant revealed that balsamin led to a dramatic decrease of
viral replication. Balsamin (3.57 mM) addition indeed resulted in
.99% inhibition of peak HIV-1 release in supernatant as
measured by both RT assay (Figure 1A) and p24 ELISA
(Figure 1B). At the end of the growth curve (11th day), the
amount of p24 in the supernatant of untreated cells was 6785 ng/
ml of p24 versus only 20 ng/ml in balsamin-treated cells. To
confirm these results, proteins were extracted from these cells on
day 11, and analyzed by Western blotting. This again demon-
strated that balsamin almost completely abolished accumulation of
HIV-1 capsid protein in cytoplasm (Figure 1C).
In order to determine the IC50 of balsamin-mediated HIV-1
inhibition, we performed a dose-response curve on Jurkat cell line
with increasing concentration of the protein. This indicated that
balsamin exerts a dose-dependent inhibition of HIV-1 viral
replication, with an IC50 value lying in the nanomolar range,
namely 10.2 nM (Figure 2A). Finally, to exclude that balsamin
antiviral effect is a consequence of a putative effect on cell health,
we assessed the effect of increasing balsamin doses on Jurkat cells
growth for 7 days (Figure 2B). In order to determine the TC50 of
Balsamin, we performed a dose-response curve on Jurkat cell lines
with increasing concentration of protein. Trypan blue exclusion
counting method (Figure 2C) and a more quantitative Annexin V/
7-AAD staining (Figure 2D) showed a TC50 of Balsamin at
,6.25 mM in Jurkat cells after 48 hours treatment. A control
experiment was performed using AZT and giving a TC50 of AZT
at ,329 mM (data not shown). Although the highest balsamin
concentration affected the viability of Jurkat cells, no significant
toxicity is observed at several doses at which balsamin already
shows considerable antiviral activity. We conclude that balsamin
potent HIV-1 inhibition is not due to a cytotoxic effect. As HIV-1
was shown to rapidly develop resistance to AZT via mutations in
the reverse transcriptase viral genes [23], we aimed to investigate
the emergence of drug-resistant escape mutants. We performed a
dose-response curve on Jurkat cells in the presence and absence of
increasing doses of protein over a period of 18 days upon HIV-1
infection. In the conditions used there was no emergence of
resistance (Figure 2E). While this, however, does not preclude the
possibility of resistance in other culture settings or indeed in vivo,
these data demonstrate that the potent antiviral activity of
balsamin is stable over time even at low concentrations.
Figure 5. Balsamin inhibits HIV-1 at the viral proteins synthesis
step. A. Primary CD4+ T cells were infected with DNase-treated single-
round HIV-1 virus at a moi of 1 and 0.2, in the absence or presence of
indicated doses of balsamin. Treatment with 50 mM AZT served as a
positive control of HIV-1 inhibition. Forty-eight hours post-infection, cell
lysates were prepared and subjected to Western blot analysis for HIV-1
p24 capsid and a-actin (as a loading control). The section of this figure
is representative of two independent experiments. B. In parallel, cell-
free supernatants were harvested from these cells 48 h of post-infection
and viral replication was assessed by RT assay. The value obtained in the
absence of balsamin at moi 1 was set as 100%. Data represent6SD and
is representative of two independent experiments performed in
duplicate.
doi:10.1371/journal.pone.0073780.g005
Balsamin Inhibits HIV-1 Replication
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Balsamin Potently Inhibits HIV-1 Replication in Primary
CD4+ T Cells
We next wanted to determine whether balsamin antiviral
activity also extends to primary T cells. For that, we assessed the
effect of increasing doses of balsamin on HIV-1 replication in these
cells. Balsamin inhibited HIV-1 replication in a dose-dependent
manner, as assessed by RT assay performed on the cells
supernatant 3 days after infection (Figure 3A). Accordingly,
intracellular HIV-1 p24 levels showed a similar dose-dependent
decrease when monitored by Western blotting of balsamin-treated
cells (Figure 3B). Importantly, measuring in parallel the cytotox-
icity of balsamin on these cells showed an absence of deleterious
effect on cell health, both over the range of balsamin doses used
and over the period of the assay (Figure 3C). As in figure 2, we
estimated the TC50 of balsamin in primary CD4+ T cells to be
,8.75 mM by both Trypan blue exclusion counting method
(Figure 3D) and Annexin V/7-AAD staining (Figure 3E). In
comparison, TC50 of AZT in primary CD4+ T cells was ,31 mM
(data not shown).We conclude that balsamin potently inhibits
HIV-1 replication in primary T cells, without affecting cellular
viability.
Investigating which viral Replication Step is Affected by
Balsamin
How RIP affect viral replication is a matter of debate [24]. To
shed some light on how balsamin inhibits HIV-1 replication, we
tried to delineate more precisely at which step of the viral
replication cycle balsamin exerts its antiviral activity. We first
infected Jurkat T cells with 2 different doses of HIV-1 and, forty-
eight hours later, viral supernatant was collected and its content in
HIV-1 RT was measured (Figure 4B), which showed that
balsamin exerted a strong effect on viral replication as expected.
In parallel, the accumulation of viral DNA in cells was monitored
by PCR (Figure 4A). This showed that balsamin had no effect on
the ability of the virus to reverse-transcribe its genome into DNA.
Heat-inactivation of viral particles prior to infection served as
negative control. This demonstrates that balsamin exerts its
antiviral activity at a step later than reverse transcription but
prior to viral particle production.
These results suggested that balsamin may exert its activity at
the translation step of viral proteins, between reverse transcription
of incoming viral genome and release of newly produced viral
particles. In order to assess this possibility, we made use of a single-
round HIV-1 system, where the virus is only capable for a single
replication cycle. This system allows to precisely monitor the
translation of viral proteins during one single round of replication,
thereby avoiding the potentially confounding effect of subsequent
rounds of replication. For that we used a HIV-1 construct that is
able to perform only a single round of viral replication, due to a
deletion of the envelope gene. The initial infection is performed
owing to the incorporation of the VSVG envelope protein in the
viral particles during the production of these viruses. During the
initial round of infection, the HIV-1 proviral genome is integrated
in the host DNA, which drives the normal transcription,
translation, assembly and release of viral proteins. However, due
Figure 6. Balsamin potently inhibits influenza virus replication. A. A549 respiratory cells were infected with influenza virus PR8 strain cells at
a moi of 1, in the absence or presence of indicated doses of balsamin, and then washed after overnight incubation. Twenty-four hours later, the
impact of balsamin on influenza virus proteins accumulation in cells was monitored by preparing cell lysates and analyzing them by Western blotting
for viral M1 matrix protein. Actin served as a loading control. The section of this figure is representative of two independent experiments. B. In
parallel, the impact of balsamin on influenza virus replication was assessed by titrating the viral content of infected cells supernatant on MDCK cells.
Data represent 6SD and representative of three independent experiments performed in duplicate.
doi:10.1371/journal.pone.0073780.g006
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to the absence of any viral glycoprotein, no infectious viruses are
produced and therefore subsequent rounds of replications are fully
abrogated [25].
Primary CD4+ T cells were infected with two different viral
doses of this single-round env-deleted HIV-1 virus. Forty-eight
hours later, viral supernatant was collected and its content in HIV-
1 RT was measured (Figure 5B), which showed that balsamin
exerted a strong effect on viral replication even in this single round
setting. Interestingly, Western blot analysis was performed in
parallel on cellular extracts showed a comparable decrease of viral
proteins accumulation in infected cells (Figure 5A). This shows
that balsamin exerts its antiviral activity at or before the translation
of viral proteins. We conclude from these results combined with
results from Figure 4 that that balsamin exerts its activity between
reverse transcription and the apparition of viral proteins, possibly
at the translation step.
Balsamin Potently Inhibits Influenza virus Replication
In order to determine whether the antiviral activity of balsamin
extends to other class of viruses, we addressed whether it was able
to inhibit replication of the influenza virus, a RNA virus possessing
a segmented negative strand genome. For that, A549 cells were
infected with the PR8 strain of influenza virus in the presence of
increasing concentration of balsamin. Twenty-four hours later, a
Western blot analysis was performed on cell extracts (Figure 6A) to
monitor the accumulation of the viral M1 protein. This
demonstrated a potent dose-dependent inhibition of influenza
replication by balsamin. Notably, visual inspection of the cells
excluded that this decrease would be due to balsamin-induced cell
suffering (data not shown). In parallel, viral supernatants were
collected, and their content of infectious particles were determined
by titration on MDCK cells (Figure 6B). This confirmed that
balsamin treatment led to a potent dose-dependent reduction of
production of new viral particles. Taken together, data suggest that
balsamin antiviral activity is active against a broad range of
viruses.
Discussion
Ribosome-inactivating proteins (RIPs) are recognized to have
various biological properties such as antimicrobial, abortifacient,
anti-tumor, immunosuppressive and antiviral activity [5,7].
Balsamin is a type I RIP recently isolated from Momordica balsamina
seeds that has N-glycosidase activity and inhibition of protein
synthesis in cell-free lysate [17]. The present study demonstrates
that balsamin exerts potent anti-HIV activity, with an IC50 of
approximately 10 nM. Balsamin indeed inhibits HIV-1 replication
in T cell lines as well as primary CD4+ T cells, as scored by several
assays, including growth curves and single-round assays, reaching
.99% inhibition in growth curve assays. Importantly, a potent
activity is observed also at doses where no significant toxicity to
cells is observed.
The exact mechanism that RIPs use to inhibit viral replication is
a matter of debate [24]. Notably it was proposed that three
isoforms of PAP (PAP-I, PAP-II and PAP-III) from Phytolacca
americana inhibited HIV-1 replication by causing dose-dependent
depurination of HIV-1 RNA. In contrast to PAP isoforms, RTA
(Toxic A chain of ricin from Ricinus communis) has no anti-HIV
activity and fails to depurinate HIV-1 RNA. Intriguingly, both
RTA and isoforms of PAP have ribosome-inactivating property,
owing to highly conserved residues. Therefore anti-HIV activity of
PAP isoforms may be due to its unique ability to depurinate HIV-
1 RNA [26]. In another set of experiment, three major proteolytic
fragments of MAP30 (Momordica charantia) and GAP31 (Gelonium
multiflorum) were generated. These were N-terminal, central
proteolytic fragment and C-terminal fragment. The central
proteolytic fragment of MAP30 and GAP31 were able to inhibit
HIV-1 p24 expression, prevent HIV-1 integration, and topolog-
ically relax supercoiled DNA but did not show any ribosome
inactivation activity, whereas C-terminal region had ribosome
inactivation activity. This suggested that anti-HIV activity of
MAP30 and GAP31 was exerted independently of ribosome
inactivating activity [27].
Finally, it was proposed that MAP30 (Momordica charantia),
GAP31 (Gelonium multiflorum), luffin (Luffa cylindrica), saporin
(Saponaria officinalis) and TCS (Trichosanthes kirilowii) affect viral
replication by inhibiting HIV-1 integrase in vitro [28,29]. In
particular, TCS (Trichosanthes kirilowii) acted on HIV-1 LTR to
specifically inhibit HIV-1 DNA integration [4]. In order to
delineate at which replicative step balsamin exerts its antiviral
action, we measured accumulation of HIV-1 reverse transcripts in
infected cells. This showed that balsamin had no effect on this step,
excluding an activity of this antiviral compound on viral entry and
reverse transcription. In addition, we showed that the effect is
already apparent shortly afterwards, at the level of accumulation of
viral proteins in the cytoplasm, strongly suggesting that balsamin
activity on protein translation underlies its antiviral activity, as was
shown by for trichosanthin anti-HIV property [30]. Such a
mechanism of action would also be consistent with the observed
absence of viral escape mutants (Figure 2E), since a mutation
rendering the viral replication independent of ribosomal transla-
tion is not possible. Accordingly, previous studies on MAP30 from
Momordica charantia showed that its anti-HIV activity is exerted by
decreasing p24 expression and viral RT activity [10]. Neverthe-
less, the exact mechanism underlying this antiviral activity is still to
be fully unraveled. Additional mechanisms participating in
antiviral potency may also be at play. In that respect, studies on
trichosanthin, another type 1 ribosome-inactivating protein,
showed that anti-HIV activity is not entirely dependent on
ribosome-inactivating activity [31]. In addition to the inhibition of
HIV-1, we here demonstrate a potent activity of balsamin against
the influenza virus, another important human pathogen. This
finding is reminiscent of the action of pokeweed antiviral protein
against this pathogen [32]. This strongly suggests that balsamin
has broad anti-viral activity, and therefore these observations may
open new therapeutic avenues for a large scope treatment of viral
infections.
Conclusions
These studies demonstrate that balsamin expressed potent anti-
HIV activity led to a decrease of viral replication. Balsamin
effectively inhibited replication of HIV-1 in a dose-dependent
manner in primary CD4+ T cells. Single-round infectivity assay
also concluded that balsamin may exert its activity at that
translation step of viral replication, between reverse transcription
of incoming viral genome and release of newly produced viral
particles. Finally, we demonstrate that balsamin antiviral activity is
broad since it also impedes influenza virus replication. Based on
these results, balsamin is a potential candidate that could be used
as an antiviral agent for the treatment of viral infections.
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